Oxytocin as a potential pharmacological tool to combat obesity
- PMID: 35192207
- PMCID: PMC9372234
- DOI: 10.1111/jne.13106
Oxytocin as a potential pharmacological tool to combat obesity
Abstract
The neuropeptide oxytocin (OT) has emerged as an important anorexigen in the regulation of food intake and energy balance. It has been shown that the release of OT and activation of hypothalamic OT neurons coincide with food ingestion. Its effects on feeding have largely been attributed to limiting meal size through interactions in key regulatory brain regions governing the homeostatic control of food intake such as the hypothalamus and hindbrain in addition to key feeding reward areas such as the nucleus accumbens and ventral tegmental area. Furthermore, the magnitude of an anorexigenic response to OT and feeding-related activation of the brain OT circuit are modified by the composition and flavor of a diet, as well as by a social context in which a meal is consumed. OT is particularly effective in reducing consumption of carbohydrates and sweet tastants. Pharmacologic, genetic, and pair-feeding studies indicate that OT-elicited weight loss cannot be fully explained by reductions of food intake and that the overall impact of OT on energy balance is also partly a result of OT-elicited changes in lipolysis, energy expenditure, and glucose regulation. Peripheral administration of OT mimics many of its effects when it is given into the central nervous system, raising the questions of whether and to what extent circulating OT acts through peripheral OT receptors to regulate energy balance. Although OT has been found to elicit weight loss in female mice, recent studies have indicated that sex and estrous cycle may impact oxytocinergic modulation of food intake. Despite the overall promising basic research data, attempts to use OT in the clinical setting to combat obesity and overeating have generated somewhat mixed results. The focus of this mini-review is to briefly summarize the role of OT in feeding and metabolism, address gaps and inconsistencies in our knowledge, and discuss some of the limitations to the potential use of chronic OT that should help guide future research on OT as a tailor-made anti-obesity therapeutic.
Keywords: energy expenditure; food intake; meal size; obesity; oxytocin.
© 2022 British Society for Neuroendocrinology. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Conflict of interest statement
Conflicts of Interest
JEB no longer has a financial interest in OXT Therapeutics, Inc., a company that had developed highly specific and stable analogs of oxytocin to treat obesity and metabolic disease. The authors’ interests were reviewed and are managed by their local institutions in accordance with their conflict of interest policies. The other authors have nothing to report.
References
- 
    - Arletti R, Benelli A, and Bertolini A, Influence of oxytocin on feeding behavior in the rat. Peptides, 1989. 10(1): p. 89–93. - PubMed
 
- 
    - Arletti R, Benelli A, and Bertolini A, Oxytocin inhibits food and fluid intake in rats. Physiol Behav, 1990. 48(6): p. 825–30. - PubMed
 
- 
    - Verbalis JG, et al., Oxytocin secretion in response to cholecystokinin and food: differentiation of nausea from satiety. Science, 1986. 232(4756): p. 1417–9. - PubMed
 
- 
    - Kirchgessner AL, Sclafani A, and Nilaver G, Histochemical identification of a PVN-hindbrain feeding pathway. Physiol Behav, 1988. 42(6): p. 529–43. - PubMed
 
- 
    - Leibowitz SF, Hammer NJ, and Chang K, Hypothalamic paraventricular nucleus lesions produce overeating and obesity in the rat. Physiol Behav, 1981. 27(6): p. 1031–40. - PubMed
 
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
- Full Text Sources
 
        